Arena Pharmaceuticals (ARNA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA)

ARNA 99.99

0.0%

Mar 15 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wolfgangrene who wrote (2122)	1/14/2014 3:03:41 PM
From: Biotech Jim	Read Replies (1) of 2274

You guys may want to watch Orexigen Therapeutics, OREX, another company in the obesity space. They had what I consider a very powerful presentation today at the JPMorgan Healthcare conference in SF. Here is a link to the slides. ir.orexigen.com The market research for their drug was very powerful IMHO. The drug candidate was formerly called Contrave but now is called NB32 due to the fact that they want the commercial name of the drug to be Contrave (ie FDA rule). There has been a checkered development history of this drug, due to the FDA wanting to them to perform a cardiovascular outcomes trial. This data is not entirely public yet, but has been submitted to the FDA and there will be a drug review by the FDA on June 10, 2014. My bet is that the stock will run up into this meeting time frame.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next